DRG Market Assessment 보고서
질환 개요 및 예측, 역학 인텔리전스, 바이오시밀러 인텔리전스, China In-depth 등 폭넓은 시장 인텔리전스를 확인해 보세요.
What Are the U.S. Market Access and Prescribing Hurdles for the Growing Number of LAMA- and LABA-Containing Competitors in the COPD Market? | Physician & Payer Forum | US | 2014
The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic treatments, namely bronchodilators and anti-inflammatory agents, which improve patients…
Digital Marketing in 2015: Why and How Pharma Must Harness a More Strategic Approach
For digital marketing to truly deliver on its potential, most pharmas have to face and fix four interrelated issues. The first has to do with reforming the organizational structure of marketing and…
Shifts in the U.S. Rheumatoid Arthritis Market Access Landscape Due to Oral Kinase Inhibitors, New Biologics, and Biosimilars: Insights from Payers and Physicians | Physician & Payer Forum | US | 2014
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
Beyond Positive Symptoms: How Receptive Are U.S. Psychiatrists and Payers to Therapies Targeting Negative or Cognitive Symptoms of Schizophrenia? | Physician & Payer Forum | US | 2014
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…
